ArticleNPJ precision oncology2025
ALKBH5-Mediated ITGB1 m6A Modification in Ovarian Cancer Progression and Immune Evasion.
Article in NPJ precision oncology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- rRGD3International journal of molecular sciences · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
Abstract
Ovarian cancer (OC) is the deadliest gynecologic malignancy, with immune evasion contributing to its poor prognosis. This study reveals that the m6A demethylase ALKBH5 enhances OC progression and immune escape by regulating ITGB1 expression. Using bulk and single-cell RNA sequencing, deep learning, and co-expression network analysis, we identified ALKBH5 as a key regulator of m6A-modified ITGB1. Functional experiments showed that ALKBH5 promotes OC cell proliferation, metastasis, and immune evasion, while its knockdown enhances T cell-mediated cytotoxicity. Public database validation further confirmed the diagnostic value of ALKBH5 and ITGB1. Mechanistically, ALKBH5 binds to ITGB1 mRNA and removes m6A modifications, increasing its stability and expression. Targeting the ALKBH5-ITGB1 axis may offer novel diagnostic biomarkers and therapeutic strategies for OC.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.